We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Asks Court to Scuttle Genentech’s Defense of Avastin Patents
Amgen Asks Court to Scuttle Genentech’s Defense of Avastin Patents
Amgen asked a federal court to declare that its newly approved biosimilar Mvasi does not violate 27 patents Genentech holds on Avastin, the reference cancer drug Genentech is trying to defend.